Verastem Nabs $32M in Series B
Boston-based Verastem has raised $32 million in Series B financing, only eight months after wrapping up a $16 million Series A round. Advanced Technology Ventures and Astellas Venture Management led the Series B, and were joined by all previous investors: Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital. The money will support ongoing research and development. Verastem is and developing drugs to treat breast and other cancers by targeting cancer stem cells.
14 July 2011•2 mins read
